AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med 19, 1288–1296 (2013).
Nos publications
Depuis sa création, l’Institut Roche a mis son expertise au profit de nombreuses publications scientifiques.
Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. Blood cancer journal, 3(8), e131.
Decaup, E., Jean, C., Laurent, C., Gravelle, P., Fruchon, S., Capilla, F., Marrot, A., Al Saati, T., Frenois, F. X., Laurent, G., Klein, C., Varoqueaux, N., Savina, A., Fournié, J. J., & Bezombes, C. (2013).
https://doi.org/10.1038/bcj.2013.32ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. The New England journal of medicine, 368(12), 1101–1110.
Friboulet, L., Olaussen, K. A., Pignon, J. P., Shepherd, F. A., Tsao, M. S., Graziano, S., Kratzke, R., Douillard, J. Y., Seymour, L., Pirker, R., Filipits, M., André, F., Solary, E., Ponsonnailles, F., Robin, A., Stoclin, A., Dorvault, N., Commo, F., Adam, J., Vanhecke, E., … Soria, J. C. (2013).
https://doi.org/10.1056/NEJMoa1214271Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro-oncology, 15(1), 41–56.
Corroyer-Dulmont, A., Pérès, E. A., Petit, E., Guillamo, J. S., Varoqueaux, N., Roussel, S., Toutain, J., Divoux, D., MacKenzie, E. T., Delamare, J., Ibazizène, M., Lecocq, M., Jacobs, A. H., Barré, L., Bernaudin, M., & Valable, S. (2013).
https://doi.org/10.1093/neuonc/nos260Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project–part 2). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 7(10), 1490–1502.
Cadranel, J., Mauguen, A., Faller, M., Zalcman, G., Buisine, M. P., Westeel, V., Longchampt, E., Wislez, M., Coudert, B., Daniel, C., Chetaille, B., Michiels, S., Blons, H., Solassol, J., De Fraipont, F., Foucher, P., Urban, T., Lacroix, L., Poulot, V., Quoix, E., … Pignon, J. P. (2012).
https://doi.org/10.1097/JTO.0b013e318265b2b5γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast cancer research : BCR, 14(3), R96.
Séveno, C., Loussouarn, D., Bréchet, S., Campone, M., Juin, P., & Barillé-Nion, S. (2012).
https://doi.org/10.1186/bcr3214Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. The Journal of pathology, 225(1), 83–95.
Hurbin, A., Wislez, M., Busser, B., Antoine, M., Tenaud, C., Rabbe, N., Dufort, S., de Fraipont, F., Moro-Sibilot, D., Cadranel, J., Coll, J. L., & Brambilla, E. (2011).
https://doi.org/10.1002/path.2897A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British journal of cancer, 105(6), 847–853.
Farace, F., Massard, C., Vimond, N., Drusch, F., Jacques, N., Billiot, F., Laplanche, A., Chauchereau, A., Lacroix, L., Planchard, D., Le Moulec, S., André, F., Fizazi, K., Soria, J. C., & Vielh, P. (2011).
https://doi.org/10.1038/bjc.2011.294Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project–part 1). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(6), 1006–1015.